An increasing number of patients with polycystic ovary syndrome worldwide is uplifting the demand for PCOS treatment. During the forecast period 2016-2024, the global polycystic ovary syndrome treatment market is estimated to expand at a steady CAGR of 4.6%, surpassing the value of US$ 1 Bn in terms of revenues. North America will continue to be the largest market for PCOS treatment, whereas Asia Pacific is projected to witness the highest CAGR over the forecast period.
Growing prevalence of polycystic ovary syndrome remains a key factor bolstering the need for new and better treatment options for PCOS. Since the disease is associated with multiple other conditions, including obesity, infertility, and hirsutism, there is a strong demand for efficient management of associated diseases. This is another crucial factor positively influencing the market growth.
For More Information Request TOC (desk of content material), Figures and Tables of the report @ http://www.persistencemarketresearch.com/market-research/polycystic-ovarian-syndrome-drugs-market/toc
Existing treatment options for polycystic ovary syndrome primarily include drug therapy but most of the available drugs exhibit low efficacy profiles and are not capable enough to meet the exact disease treatment needs. Over the forecast period, the market is expected to witness a large number of opportunities in therapeutic development. Rising awareness about PCOS and available treatments is steadily supporting the market since the recent past.
Rapid R&D activities are also estimated to propel the market on a global level. Researchers are taking efforts toward development of highly efficient drugs that precisely target the root etiology and pathophysiology of PCOS progression. New, better treatment options are expected to sway the market by 2021 end, in addition to a strong possibility of emergence of new entrants. Growing adoption of combination drugs will also push the market growth over the forecast period.
Generic drugs are readily available but typically pose side effects. On contrary, FDA-approved drugs do not pose any ill effects but face scarcity. This is a major factor hampering the pace of market growth by 2024 end. A variety of branded drugs are trialed clinically, anticipated to enter the global market in the near future.
Based on drug class, the global market for PCOS treatment will witness the highest traction in oral contraceptive drug class segment, reaching a value of US$ 355.7 Mn at a moderate CAGR of 5.4% by 2024 end. Insulin sensitizing drugs and anti-depressants will continue to be the second and third largest segments, expanding at the CAGRs of 4.8% and 3% respectively. Other segments, including diuretics, ornithine decarboxylase inhibitors, and aromatase inhibitors will witness an uptick.
On the basis of distribution channel, the market is highly concentrated in hospital pharmacies segment, with nearly half of the total market share in 2016. This segment will continue to dominate the global market during the forecast period as well. Among other segments, including drug stores/OTC, fertility clinics, and E-commerce stores, the latter is expected to witness significant growth at a CAGR of 4.3% by 2024 end.
By region, the global PCOS treatment market will witness continued dominance by North America, followed by Europe. Both the regions will collectively account for over 60% of the market share. The market is projected to witness an upswing in developing economies, including Asia Pacific and Latin America, recording the fastest growth over the forecast period.
Some of the key players competing in the market include Sanofi, Novartis, AstraZeneca Plc., Merck KGaA, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., Biocinese, Biocad, Neurocrine Biosciences, Inc., Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Eugonia, Ferring Pharmaceuticals, Inc., Reliance Life Sciences Pvt. Ltd., EffRx, Inc., and Shire Plc. Leading companies are primarily focusing on novel drug development for polycystic ovary syndrome.
Download Report Sample @ http://www.persistencemarketresearch.com/samples/3682
Long-term Outlook: The global market for polycystic ovary syndrome treatment will surpass revenues of US$ 1 Bn by the end of 2024. The market will expand at a CAGR of 4.6% over 2016-2024.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353